Results 231 to 240 of about 120,218 (287)

Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy. [PDF]

Curr Oncol
Seipel K, Shaforostova I, Nilius H, Bacher U, Pabst T.   +4 more
europepmc   +1 more source

Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma

The FEBS Journal, EarlyView.
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris, Paraskevi Ioannou, Nikolaos A. Afratis   +2 more
wiley   +1 more source

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects. [PDF]

Front Immunol
Wang JW, Feng YF, Liu JH.
europepmc   +1 more source

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade. [PDF]

J Immunother Cancer
Arias-Badia M, Pai CS, Lwin YM, Chen P, Srinath A, Tanaka M, Musser E, Goodearl A, Gorman JV, Ritacco W, Fong L.   +10 more
europepmc   +1 more source

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Lack of Negative Feedback Loops of CTLA-4 and PD-L1 as Key Mechanisms for Post-Acute T Cell Activation Until 3 Months After Ischemic Stroke. [PDF]

Int J Mol Sci
Peglau L, Ruhnau J, Winkelmann M, Krüger T, Dressel A, Schulze J, Vogelgesang A.   +6 more
europepmc   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study. [PDF]

Cell Rep Med
Ma Y, Lin S, Chen Q, Xue J, Yang Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, Jin C, Zhu D, Li Q, Liu X, Su W, Ba Y, Li W, Li Q, Zhu C, Huang Z, Kang X, Xue S, Li H, Wang C, Luo F, Huang Y, Zhang L, Zhao H.   +30 more
europepmc   +1 more source

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. [PDF]

Cancer Immunol Immunother
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K.   +33 more
europepmc   +1 more source